Yoav Golanbw

Yoav Golan, MD, MS

Scientific Advisory Board

Dr. Golan is an attending physician at the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, Boston and an Associate Professor of Medicine at Tufts University School of Medicine. Dr. Golan is a graduate of the Hadassah School of Medicine at the Hebrew University in Jerusalem, Israel. He completed a medicine residency and Infectious Diseases fellowship at the Tel Aviv Sourasky Medical Center, followed by a transplant ID fellowship and masters in statistics and modelling at Tufts University School of Medicine. His research focuses on hospital-acquired infections with emphasis on ICU infections, the impact of antibiotic resistance on outcomes, patient risk stratification, and development of early culture-independent treatment strategies. Over the past seven years, Dr. Golan’s research has focused on C. difficile infections as well as MRSA and invasive Candidiasis. He is particularly interested in recurrent disease and the effectiveness and affordability of new treatment strategies when stratified by patients’ risk of recurrence. Dr. Golan has been involved in the development of multiple anti-infectives, including, fidaxomicin, surotomycin and bezlotuximab. He is the author of numerous manuscripts and several book chapters.

eric_brownbw

Eric Brown, PhD

Scientific Advisory Board

Dr. Brown is a Professor in the Department of Biochemistry and Biomedical Sciences and member of the M.G. DeGroote Institute for Infectious Disease Research at McMaster University. Dr. Brown has been the recipient of a number of awards including the Canadian Society of Microbiologists Murray Award for career achievement, the Canadian Society for Molecular Biosciences Merck Frosst Prize for new investigators and a Canada Research Chair in Microbial Chemical Biology. Dr. Brown is a former department Chair and has served on advisory boards for a variety of companies as well as national and international associations. Dr. Brown’s research interest is the complex biology that underlies bacterial survival strategies and aim to understand and subvert these systems in drug resistant superbugs. The Brown lab research group is using tools of chemical biology and molecular genetics to probe poorly understood aspects of bacterial physiology and has made remarkable advances by developing avant-garde chemical screening assays that have yielded exciting new probes of bacterial cell systems. The overriding goal of these studies is to contribute fresh directions for new antibacterial therapeutics and their work has yielded breakthrough lead compounds for the next generation of antibiotics.

Sridhar Narayanbw

Sridhar Narayan, PhD

Scientific Advisory Board

Dr. Narayan has spent over 9 years in large pharmaceutical companies. As a medicinal chemistry project leader at AstraZeneca and Eisai, Dr. Narayan successfully led teams working on various drug-discovery programs ranging from hit identification and lead optimization through candidate nomination and IND filing. He led the chemistry team on the discovery of a first in class TLR7 antagonist for the treatment of lupus. Due to his experience in the pharmaceutical industry, Dr. Narayan is intimately familiar with the process of optimizing pharmacokinetics, metabolism, toxicity and other parameters of candidate compounds, as well as managing external research at CROs. Dr. Narayan joined Navitor Pharmaceuticals as the Director of Medicinal Chemistry in July 2015, where he is leading multiple projects on the discovery of small molecule modulators of the mTOR pathway for the treatment of metabolic diseases. Dr. Narayan is also advisor for Appili on aspects of the API-1503 program including medicinal chemistry, primary and secondary assays, X-ray crystallography and computer-aided drug design.